Background: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coronary syndrome in 18924 patients. Alirocumab reduced first occurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina-as well as total nonfatal cardiovascular events and all-cause deaths. The present analysis determined whether alirocumab reduced total (first and subsequent) hospitalizations and death and increased days alive and out of hospital (DAOH) and percent DAOH i...
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis ...
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis ...
BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic...
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Synd...
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Synd...
BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndr...
BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndr...
The authors thank the patients, study coordinators, and investigators who participated in this tri...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Synd...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
bastos, jose/0000-0002-9526-3123; Manakshe, Gajendra/0000-0002-4983-4271; Tse, Hung Fat/0000-0002-95...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis ...
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis ...
BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic...
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Synd...
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Synd...
BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndr...
BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndr...
The authors thank the patients, study coordinators, and investigators who participated in this tri...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Synd...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
bastos, jose/0000-0002-9526-3123; Manakshe, Gajendra/0000-0002-4983-4271; Tse, Hung Fat/0000-0002-95...
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demo...
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis ...
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis ...
BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic...